{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 1-(4-Methylphenyl)-2-methylamino-pentan-1-one
| image = 4-Methylpentedrone.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = 
| legal_CA = Schedule I
| legal_UK = Class B
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1373918-61-6
| ATC_prefix = 
| ATC_suffix =  
| PubChem = 
| ChemSpiderID_Ref = 

| ChemSpiderID = 58951581

<!--Chemical data-->
| C=13 | H=19 | N=1 | O=1 
| molecular_weight = 
| smiles = CCCC(NC)C(=O)c1ccc(C)cc1
| StdInChI_Ref = 
| StdInChI          = 1S/C13H19NO/c1-4-5-12(14-3)13(15)11-8-6-10(2)7-9-11/h6-9,12,14H,4-5H2,1-3H3
| StdInChIKey_Ref = 
| StdInChIKey       = AKVKBEDACKJNPO-UHFFFAOYSA-N
}}

'''4-Methylpentedrone''' (also known as '''4-MPD''' and '''4-Methyl-α-methylamino-valerophenone'''), is a [[stimulant]] drug of the [[Substituted cathinone|cathinone]] class that has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/9002180 | title=4-Methylpentedrone | publisher=Cayman Chemical | accessdate=28 June 2015}}</ref> It is a higher homologue of [[Mephedrone|4-Methylmethcathinone]] (Mephedrone) and [[4-Methylbuphedrone]] (4-MeMABP), and the p-Methyl [[Structural analog|analogue]] of [[Pentedrone]].

The monoamine transporter substrate and I hi it ion selectivity profiles of 4-MPD are unknown.

Another compound, 4-Methyl-N-Ethyl-Pentedrone (4-MEAP, 4-MEAPP) has been found to be incorrectly sold as 4-Methylpentedrone.<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1111/1556-4029.12712/abstract | title=Identification of 2-(ethylamino)-1-(4-methylphenyl)-1-pentanone (4-MEAP), a New "Legal High" Sold by an Internet Vendor as 4-Methyl Pentedrone | author=Danielle Hamby M.Sc | author2=Annessa Burnett B.S | author3=Michael Jablonsky Ph.D| author4=Brendan Twamley Ph.D | author5=Pierce V. Kavanagh Ph.D| author6=Elizabeth A. Gardner Ph.D | journal=Journal of Forensic Sciences |date=May 2015  | volume=60 | issue=3 | pages=721–726, | doi=10.1111/1556-4029.12712 | pmid=25923458}}</ref><ref>{{cite journal | url=http://www.fsijournal.org/article/S0379-0738%2814%2900115-7/abstract | title=Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products | author=Nahoko Uchiya | author2=Satoru Matsuda | author3=Maiko Kawamura| author4=Yoshihiko Shimokawa | author5=Ruri Kikura-Hanajiri| author6=Kosuke Aritake | author7=Yoshihiro Urade| author8=Yukihiro Goda | journal=Forensic Science International |date=October 2014  | volume=243 | pages=1–13 | doi=10.1016/j.forsciint.2014.03.013 | pmid=24769262}}</ref>

==See also==
* [[Buphedrone]]
* [[Substituted cathinone]]

== References ==
{{Reflist}}

{{Stimulants}}
{{Phenethylamines}}

{{DEFAULTSORT:Methylpentedrone, 4-}}
[[Category:Cathinones]]
[[Category:Designer drugs]]
[[Category:Norepinephrine-dopamine reuptake inhibitors]]


{{nervous-system-drug-stub}}